Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 20, 2016

ContraVir reports positive Phase IIa trial data of tenofovir exalidex to treat Hepatitis B infection

US-based biopharmaceutical company ContraVir has reported positive data from its ongoing Phase IIa trial of tenofovir exalidex (TXL) to treat Hepatitis B infection.

US-based biopharmaceutical company ContraVir has reported positive data from its ongoing Phase IIa trial of tenofovir exalidex (TXL) to treat Hepatitis B infection.

TXL has been developed as a potent analog based on the successful antiviral drug tenofovir.

It features a liver-targeting structure that decreases circulating levels of tenofovir, thereby lowering systemic exposure and reducing chances of renal side effects.

The Phase IIa, multiple ascending-dose clinical trial is being conducted to evaluate tenofovir exalidex while treating 84 treatment-naïve patients with chronic HBV infection.

The study featured a sequential dose escalation format, according to which ten patients were divided in each cohort to receive daily dosages of 5mg, 10mg, 25mg, 50mg, 100mg, 150mg and 200mg of TXL, with two patients per cohort receiving 300mg of tenofovir disoproxil fumarate (TDF).

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Results suggested that TXL has exhibited increased anti-viral activity while administered in its highest dose of 100mg.

"We believe demonstrating this unique profile for TXL may open many doors in terms of developing new combination therapies for HBV that have curative potential."

ContraVir CEO James Sapirstein said: "We are pleased with the antiviral profile that is being exhibited by TXL at this first stage in our clinical evaluation of this drug in HBV patients.

"TXL has shown an excellent safety profile, and we are encouraged that as we go to higher doses above 100mg we may see even greater antiviral activity with a continued excellent safety profile.

"We believe demonstrating this unique profile for TXL may open many doors in terms of developing new combination therapies for HBV that have curative potential."

Prompted by the positive data, the company is now planning to evaluate 150mg dosage of TXL following recent clearance of the product by the independent data safety monitoring board (DSMB).


Image: Ground glass hepatocytes seen in chronic hepatitis B liver biopsy. Photo: courtesy of Nephron.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU